Neil Woodford has invested £16m in a US biotech company working on brain tumour treatment.
The manager, who now runs his own firm Woodford Investment Management, has invested £16m in Northwest Biotheraputics which is based in Maryland, the Telegraph reports. The company said it would use the additional cash to expand its clinical programme where it plans to run Phase II trials in two cancer variants. It previously produced the first medicine to be fast-tracked by the Department of Health for a brain cancer vaccine. Woodford (pictured) has a bias towards biotech and pharmaceutical companies within his £3.3bn Woodford Equity Income fund. Some 33% of his fund is allocat...
To continue reading this article...
Join Professional Adviser for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, industry insights and market intelligence
- Stay ahead of the curve with spotlights on emerging trends and technologies
- Receive breaking news stories straight to your inbox in the daily newsletters
- Make smart business decisions with the latest developments in regulation, investing retirement and protection
- Members-only access to the editor’s weekly Friday commentary
- Be the first to hear about our events and awards programmes
